Fresh analysis suggests that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who end traditional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while overweight individuals often shed a large proportion of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals buying such drugs need to be aware of the risk of quick weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to starting mass in about a year and a half.
Comparing Therapies
The analysis, which looked at dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills.
Scientists note that people who lose weight through lifestyle changes alone usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Nutrition scientists believe the mechanism of the drugs accounts for the accelerated weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Health authorities advise the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts say that, due to the significant potential of weight regain, the treatment should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term character of obesity," akin to managing diseases like high blood pressure.
Patient Testimonies
People who have come off the jabs explain a sudden resurgence of hunger.
"It felt as if something flipping and I was suddenly starving," described one woman.
This challenge is worsened if users have not developed lasting lifestyle or habit changes during therapy.
Significant Use
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is greater among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, experts stress that while these medications are effective tools for shedding pounds, they are not a standalone cure and long-term success relies on ongoing behavioural support.
